Literature DB >> 7682093

Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.

C Kalifa, H Razafindrakoto, G Vassal, G Contesso, D Vanel, V Edeline, D Valteau, J Lemerle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7682093     DOI： 10.1007/978-1-4615-3518-8_42

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  6 in total

Review 1.  Methotrexate for high-grade osteosarcoma in children and young adults.

Authors:  Elvira C van Dalen; Jorrit W van As; Beatriz de Camargo
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

2.  Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial.

Authors:  H Assi; G Missenard; P Terrier; C Le Pechoux; S Bonvalot; D Vanel; J B Meric; T Tursz; A Lecesne
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

3.  Expression change of ezrin as a prognostic factor in primary osteosarcoma.

Authors:  Yao Fei Wang; Jing Nan Shen; Xian Biao Xie; Jin Wang; Gang Huang
Journal:  Med Oncol       Date:  2010-09-22       Impact factor: 3.064

4.  Clinical value of ezrin expression in primary osteosarcoma.

Authors:  Chan Kim; Eunah Shin; Soojung Hong; Hong Jae Chon; Hye Ryun Kim; Jung Ryun Ahn; Min Hee Hong; Woo Ick Yang; Jae Kyung Roh; Sun Young Rha
Journal:  Cancer Res Treat       Date:  2009-09-28       Impact factor: 4.679

5.  Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma.

Authors:  Sébastien Salas; Carine Jiguet-Jiglaire; Loic Campion; Catherine Bartoli; Frédéric Frassineti; Jean-Laurent Deville; André Maues De Paula; Fabien Forest; Pascal Jézéquel; Jean-Claude Gentet; Corinne Bouvier
Journal:  BMC Cancer       Date:  2014-08-20       Impact factor: 4.430

6.  Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.

Authors:  Liliana Vasquez; Fanny Tarrillo; Monica Oscanoa; Ivan Maza; Jenny Geronimo; Gloria Paredes; Jose María Silva; Luis Sialer
Journal:  Front Oncol       Date:  2016-02-02       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.